Compare RL & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RL | GH |
|---|---|---|
| Founded | 1967 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.2B | 20.6B |
| IPO Year | 1997 | 2018 |
| Metric | RL | GH |
|---|---|---|
| Price | $379.94 | $144.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 17 | 19 |
| Target Price | ★ $406.75 | $119.79 |
| AVG Volume (30 Days) | 522.0K | ★ 2.4M |
| Earning Date | 05-21-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.01% | N/A |
| EPS Growth | ★ 30.15 | 6.74 |
| EPS | ★ 15.11 | N/A |
| Revenue | ★ $8,114,500,000.00 | $982,021,000.00 |
| Revenue This Year | $15.92 | $33.30 |
| Revenue Next Year | $5.80 | $28.27 |
| P/E Ratio | $24.72 | ★ N/A |
| Revenue Growth | 14.63 | ★ 32.88 |
| 52 Week Low | $273.04 | $40.36 |
| 52 Week High | $421.60 | $174.08 |
| Indicator | RL | GH |
|---|---|---|
| Relative Strength Index (RSI) | 47.47 | 46.90 |
| Support Level | $366.66 | $94.02 |
| Resistance Level | $383.30 | $174.08 |
| Average True Range (ATR) | 12.76 | 7.45 |
| MACD | -1.57 | -3.03 |
| Stochastic Oscillator | 38.21 | 6.24 |
Founded by designer Ralph Lauren (current executive chairman and chief creative officer) in 1967 in New York City, Ralph Lauren Corp. designs, markets, and distributes lifestyle merchandise in North America, Europe, and Asia. Best known for its iconic polo shirts, its products also include other types of apparel, footwear, eyewear, jewelry, handbags, home goods, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, and Lauren Ralph Lauren. Distribution channels for Ralph Lauren include wholesale (department stores and specialty stores), retail (company-owned retail stores and e-commerce), and licensing.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.